Cargando…

The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level

Detalles Bibliográficos
Autores principales:	Schinke, Carolina, Weinhold, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219691/ https://www.ncbi.nlm.nih.gov/pubmed/37251913 http://dx.doi.org/10.1097/HS9.0000000000000894

Ejemplares similares

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
por: John, Lukas, et al.
Publicado: (2023)

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
por: Pilcher, William, et al.
Publicado: (2023)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
por: Gámez, Beatriz, et al.
Publicado: (2021)

Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
por: Wang, Jin, et al.
Publicado: (2022)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
por: Lopes, Raquel, et al.
Publicado: (2021)

Therapeutics to harness the immune microenvironment in multiple myeloma
por: Ignatz-Hoover, James J., et al.
Publicado: (2022)

Single-cell RNA-Seq unveils tumor microenvironment
por: Lee, Hae-Ock, et al.
Publicado: (2017)

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
por: García-Ortiz, Almudena, et al.
Publicado: (2021)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Multiple myeloma in Korea: risk stratification and initial treatment
por: Yoon, Sung-Soo
Publicado: (2018)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
por: Mohan, Meera, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Progress in mimicking brain microenvironments to understand and treat neurological disorders
por: Ngo, Mai T., et al.
Publicado: (2021)

Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma
por: Ahn, Sungwoo, et al.
Publicado: (2021)

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma
por: Garcés, Juan-José, et al.
Publicado: (2022)

Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory
por: Capp, Jean-Pascal, et al.
Publicado: (2020)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
por: Xu, Xu Steven, et al.
Publicado: (2017)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma
por: Wu, Shaojie, et al.
Publicado: (2021)

Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment
por: Lopes, Raquel, et al.
Publicado: (2022)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
por: Du, Jianhua, et al.
Publicado: (2021)

Involvement of lncRNAs in the tumor microenvironment: a new property of tumor immunity
por: Lin, Qingyu, et al.
Publicado: (2023)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Targeting the Microenvironment for Treating Multiple Myeloma
por: Neumeister, Peter, et al.
Publicado: (2022)

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
por: Giannotta, Claudia, et al.
Publicado: (2023)

Modeling the tumor immune microenvironment for drug discovery using 3D culture
por: Lee, Joanna Y., et al.
Publicado: (2021)

The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment
por: Jurczyszyn, Artur, et al.
Publicado: (2015)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

A critical role for the NFkB pathway in multiple myeloma
por: Demchenko, Yulia N., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_opsci3pefc4gprlsnaahp2f73h